Related Experiment Video
Updated: Nov 11, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer
Mark R Openshaw1, David J Pinato1,2, Nicola Valeri3,4,5,6
1Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom.
Abstract:
Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.See related article by Corso et al., p. 3126.
Insights
Gastroesophageal adenocarcinomas (GEA) are hard to treat. However, a new study suggests that epidermal growth factor receptor inhibitors (EGFRi) may be effective in specific GEA patient groups, potentially reviving their development.
Area of Science:
- Oncology
- Gastroenterology
- Molecular Biology
Background:
- Gastroesophageal adenocarcinomas (GEA) present significant treatment challenges with limited targeted options.
- Previous trials of epidermal growth factor receptor inhibitors (EGFRi) in unselected GEA populations yielded negative results, hindering further development.
Purpose of the Study:
- To re-evaluate the efficacy of EGFR inhibitors in gastroesophageal adenocarcinomas.
- To identify potential patient subgroups who may benefit from EGFR-targeted therapy.
Main Methods:
- Analysis of recent clinical trial data.
- Molecular profiling of gastroesophageal adenocarcinoma patient cohorts.
Main Results:
- Emerging data suggests a potential role for EGFR inhibitors in specific GEA patient subsets.
- This may reopen avenues for EGFRi development in gastroesophageal cancer.
Conclusions:
- A recent study indicates that EGFR inhibitors might be viable for certain GEA patients.
- This finding could revitalize the therapeutic development of EGFRi for gastroesophageal cancers.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Barrett Esophagus-I: Introduction
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
Gastroesophageal Reflux Disease I: Meaning and Pathophysiology
Esophageal Strictures-I: Introduction
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...

